Daily Respiratory Research Analysis
Three papers markedly advance respiratory health: (1) a multicenter phase 3 trial shows a single 40‑mg oral dose of the novel PA endonuclease inhibitor suraxavir marboxil shortens influenza symptom duration and reduces viral load; (2) a randomized trial indicates biomarker-guided EarlyCDT-Lung screening can reduce lung cancer mortality at 5 years; (3) a preclinical ‘hybrid’ influenza B HA vaccine strategy achieves cross-lineage protection in ferrets.
Summary
Three papers markedly advance respiratory health: (1) a multicenter phase 3 trial shows a single 40‑mg oral dose of the novel PA endonuclease inhibitor suraxavir marboxil shortens influenza symptom duration and reduces viral load; (2) a randomized trial indicates biomarker-guided EarlyCDT-Lung screening can reduce lung cancer mortality at 5 years; (3) a preclinical ‘hybrid’ influenza B HA vaccine strategy achieves cross-lineage protection in ferrets.
Research Themes
- Novel antivirals for respiratory infections
- Biomarker-guided screening and precision prevention
- Next-generation vaccine design for cross-lineage protection
Selected Articles
1. Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
In a 591-participant, double-blind phase 3 trial, a single 40 mg oral dose of suraxavir marboxil significantly reduced time to alleviation of influenza symptoms (median 42 vs 63 h) and accelerated viral load decline compared with placebo. Safety and secondary outcomes, including systemic and respiratory symptoms, supported clinical benefit across uncomplicated influenza A/B.
Impact: Demonstrates efficacy of a single-dose, novel PA endonuclease inhibitor against influenza, potentially changing outpatient management with simplified dosing and rapid virologic effects.
Clinical Implications: A single oral dose could streamline treatment, improve adherence, and reduce transmission windows; comparative studies vs active antivirals and high-risk populations will inform guidelines.
Key Findings
- Single 40 mg dose reduced time to alleviation of influenza symptoms (median 42.0 h vs 63.0 h; P=0.002).
- More rapid viral load decline by day 1 post-dose (mean −2.2±1.3 vs −1.3±1.7 log units vs placebo).
- Efficacy observed across uncomplicated influenza A and B in otherwise healthy outpatients.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled phase 3 design
- Prespecified, clinically meaningful primary endpoint (TTAS) with objective virologic secondary measures
Limitations
- Trial conducted in China; generalizability to diverse global populations and high-risk groups requires study
- No active comparator against oseltamivir/baloxavir; limited data on hospitalization or complications
Future Directions: Head-to-head trials versus standard antivirals, evaluation in high-risk and elderly populations, resistance surveillance (PA variants), and health-economic analyses of single-dose strategies.
Suraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza. It has shown therapeutic activity against influenza A and B virus infections in preclinical studies. In this multicenter randomized, double-blind, placebo-controlled, phase 3 trial, we aimed to investigate the efficacy and safety of single-dose suraxavir marboxil (40-mg oral dose) in otherwise healthy outpatients aged 5-65 years with uncomplicated influenza unaccompanied by severe issues. From 28 July 2022 to 31 October 2023, 591 outpatients aged 5-65 years with uncomplicated influenza underwent randomization in 46 research centers in China and were randomly assigned in a 2:1 ratio to receive suraxavir marboxil (40 mg) or placebo within 2 days of symptom onset. The primary outcome was time to alleviation of influenza symptoms (TTAS) (from the start of treatment until body temperature returned to 37.2 °C or less and all seven influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) resolved for at least 21.5 h) within 15 days by treatment. The secondary endpoints included virological indicators, system and respiratory symptoms, PA variant mutation and adverse events. The median TTAS was significantly shorter in the group that received suraxavir marboxil compared to the placebo group (42.0 h versus 63.0 h, P = 0.002). Suraxavir marboxil was associated with more rapid decrease in viral load from baseline than placebo by 1 day after administration, with a mean change of -2.2 ± 1.3 compared to -1.3 ± 1.7 log
2. Development of broadly protective influenza B vaccines.
By engineering ‘hybrid’ HA antigens with reciprocal lineage-specific substitutions, the authors generated vaccine candidates that enhanced heterologous protection in ferrets compared to wild-type HA, indicating a path toward cross-lineage influenza B vaccines.
Impact: Addresses a long-standing antigenic split in influenza B with a rational protein-engineering approach that could reduce mismatch risk and simplify vaccine strain selection.
Clinical Implications: If translated to humans, cross-lineage HA vaccines could improve effectiveness across seasons, reduce need for precise lineage prediction, and bolster pandemic preparedness for IBV.
Key Findings
- Hybrid HA antigens with reciprocal substitutions at lineage-differing sites were designed and produced.
- Antigenic characterization identified two lead candidates with cross-lineage potential.
- In ferrets, recombinant hybrid HAs conferred stronger protection against heterologous lineage challenge than wild-type antigens.
Methodological Strengths
- Rational antigen design grounded in lineage-differentiating residues with antigenic characterization
- In vivo validation in ferret challenge model demonstrating heterologous protection
Limitations
- Preclinical animal study; no human immunogenicity or efficacy data yet
- Durability of cross-lineage protection and manufacturing scalability not assessed
Future Directions: Advance to human immunogenicity trials, map protective epitopes, assess durability and breadth, and evaluate manufacturability and regulatory pathways for cross-lineage candidates.
Influenza B viruses pose a significant threat to global public health, leading to severe respiratory infections in humans and, in some cases, death. During the last 50 years, influenza B viruses of two antigenically distinct lineages (termed 'Victoria' and 'Yamagata') have circulated in humans, necessitating two different influenza B vaccine strains. In this study, we devised a novel vaccine strategy involving reciprocal amino acid substitutions at sites where Victoria- and Yamagata-lineage viruses differ, leading to the generation of 'hybrid' vaccine viruses with the potential to protect against both lineages. Based on antigenic characterization, we selected two candidates and assessed their protective efficacy in a ferret model. Notably, both recombinant HA proteins conferred enhanced protection against heterologous challenges compared to their respective wild-type antigens. These findings show the potential of our novel strategy to develop cross-lineage protective influenza B virus vaccines.
3. Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
In a pragmatic RCT of 12,208 high-risk adults, biomarker-guided selection (EarlyCDT-Lung) for LDCT screening was associated with reduced lung cancer mortality at 5 years (adjusted HR 0.789), with stronger benefits among cancers diagnosed within two years of randomization.
Impact: Provides rare randomized evidence that biomarker-guided, risk-targeted screening can improve survival, informing precision screening strategies beyond age/pack-year criteria.
Clinical Implications: Health systems could integrate blood-based autoantibody testing to triage LDCT eligibility, potentially improving screening efficiency and reducing mortality in high-risk populations.
Key Findings
- Biomarker-guided arm had fewer lung cancer deaths at 5 years (adjusted HR 0.789; 95% CI 0.636–0.978).
- Among cancers diagnosed within 2 years, all-cause mortality HR 0.615 and lung cancer mortality HR 0.598 favored biomarker-guided selection.
- Randomized 12,208 high-risk adults; outcomes ascertained via death and cancer registries in a pragmatic design.
Methodological Strengths
- Large pragmatic randomized design with 5-year registry-based outcomes
- Mortality endpoints and prespecified subgroup analysis by time-from-randomization
Limitations
- Open-label screening strategy; potential differences in downstream management
- Generalizability and cost-effectiveness in diverse healthcare systems require evaluation
Future Directions: Head-to-head comparisons with risk models, integration with polygenic and clinical risk, and cost-effectiveness and implementation studies in varied health systems.
The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low dose Computed Tomography (LDCT) screening for those at highest risk. We randomized 12 208 individuals aged 50-75 at high risk of developing lung cancer to either the test or to standard clinical care. Outcomes were ascertained from Register of Deaths and Cancer Registry. Cox proportional hazards models were used to estimate the hazard ratio of the rate of deaths from all causes and lung cancer. Additional analyses were performed for cases of lung cancer diagnosed within two years of the initial test. After 5 years 326 lung cancers were detected (2.7% of those enrolled). The total number of deaths reported from all causes in the intervention group was 344 compared to 388 in the control group. There were 73 lung cancer deaths in the intervention arm and 90 in the controls (Adjusted HR 0.789 (0.636, 0.978). An analysis of cases of lung cancer detected within 2 years of randomization in the intervention group showed that there were 34 deaths from all causes and 29 from lung cancer. In the control group there were 56 deaths with 49 from lung cancer. In those diagnosed with lung cancer within 2 years of randomization the hazard ratio for all cause mortality was 0.615 (0.401,0.942) and for lung cancer 0.598 (0.378, 0.946). Further large-scale studies of the role of biomarkers to target lung cancer screening, in addition to LDCT, are likely to provide additional value.